Antibody-based therapeutics targeting ILDR2, designated by Compugen as CGEN-15001T, for immuno-oncology were licensed to Bayer, while Compugen retains the full rights to the fusion protein ...

Do not miss out and become a member today for free to access this upcoming report at: Compugen, First to Publish Data on ILDR2 as a New Immune Checkpoint with a Therapeutic Role in Auto-Immune ...

BAY 1905254 is a novel immune checkpoint inhibitor for cancer immunotherapy targeting ILDR2. BAY 1905254 is a human/mouse cross-reactive antibody designed to block the immunosuppressive activity ...

Lastly, Compugen's final disclosed therapeutic is BAY 1905254 (Phase 1), an ILDR2-targeting antibody licensed to Bayer for treating advanced solid tumors. Compugen’s therapeutic pipeline also ...

One is CGEN-15001T/ILDR2, which is being developed by Bayer under a 2013 agreement. On February 21, Compugen said Bayer was advancing CGEN-15001T through late preclinical development, with plans ...

BAY 1905254 is a first-in-class therapeutic antibody candidate targeting ILDR2, a novel immune checkpoint discovered by Compugen. Bayer plans to advance the program into first-in-human trials in 2018.

Immunohistochemistry plays a key role in the diagnosis of soft tissue tumors. Until recently, however, the primary purpose of immunohistochemistry in this context was simply to attempt to ...

BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting ILDR2 immune checkpoint discovered by Compugen, is currently being evaluated by Bayer in a Phase 1 study in advanced ...

Stock Monitor: Array BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 08, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN ...